Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Endo International (ENDP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Endo (ENDP)
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Endo (ENDP) Down 33% Since Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.
Mallinckrodt Up on New York's Support for Opioid Settlement
by Zacks Equity Research
Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.
Implied Volatility Surging for Endo International (ENDP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4
by Zacks Equity Research
Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.
Endo International (ENDP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 29.82% and 5.25%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks
by Sweta Killa
The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.
Here's Why You Should Add BioDelivery Stock to Your Portfolio
by Zacks Equity Research
Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.
J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge
by Zacks Equity Research
A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.
Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
by Zacks Equity Research
Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.
Will J&J be Able to Overcome Its Legal Troubles in 2020?
by Indrajit Bandyopadhyay
Here we discuss the growth potential of J&J's (JNJ) stock in 2020.
Implied Volatility Surging for Endo (ENDP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.
Why Is Endo (ENDP) Up 12.3% Since Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Options Traders Expect Huge Moves in Endo (ENDP) Stock
by Zacks Equity Research
Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
by Zacks Equity Research
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
by Zacks Equity Research
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA
by Zacks Equity Research
The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.
Company News For Nov 21, 2019
by Zacks Equity Research
Companies in the news are: URBN, KNSA, ACB, ENDP
BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View
by Madhu Goel
BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.
Endo International (ENDP) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 13.21% and 3.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Endo International (ENDP) Q3 Earnings Expected to Decline
by Zacks Equity Research
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.